{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:18:24Z","timestamp":1795141104188,"version":"4.10.3"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess the structural and functional outcomes of treatment with ciliary neurotrophic factor for patients with Type 2 macular telangiectasia (MacTel).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Studies were retrieved from inception to May 2024 from MEDLINE, Embase, and Cochrane Library databases. The primary outcome was final best-corrected visual acuity and changes in best-corrected visual acuity from baseline, while ellipsoid zone discontinuity area was a secondary outcome. Risk of bias for observational studies and randomized clinical trials were assessed using the ROBINS-1 tool and Cochrane ROB2 tools, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Five studies reporting on 498 eyes of 422 patients were included in this systematic review. One randomized clinical trials of 99 eyes found decreased progression of retinal degeneration and reduced decline in reading speed in implant-treated eyes compared with sham-treated eyes. An uncontrolled Phase 1 safety trial involving 14 eyes in 7 patients with MacTel undergoing ciliary neurotrophic factor therapy demonstrated good tolerance, with no significant differences in visual acuity or retinal sensitivity between treated and untreated eyes over 36 months, although five participants experienced persistent miosis in the implanted eye. One study highlighted smaller changes in ellipsoid zone defect areas in ciliary neurotrophic factor\u2014treated eyes compared with sham-treated eyes. Recently published data demonstrated significant structural progression slowing, although functional outcomes were variable and safety was comparable with sham aside from increased delayed dark adaptation and miosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ciliary neurotrophic factor therapy seems to slow retinal degeneration and preserve visual function in patients with MacTel. While ciliary neurotrophic factor shows promise for earlier stages of MacTel, further trials are required to fully assess its long-term efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004852","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:02:09Z","timestamp":1775743329000},"page":"1505-1512","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["CILIARY NEUROTROPHIC FACTOR THERAPY FOR MACULAR TELANGIECTASIA TYPE 2"],"prefix":"10.1097","volume":"46","author":[{"given":"Aswen","family":"Sriranganathan","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zwetlana","family":"Rajesh","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grad","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha P.","family":"Kohly","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;"},{"name":"Department of Ophthalmology, St. Michael's Hospital\/Unity Health Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.preteyeres.2012.11.002","article-title":"Macular telangiectasia type 2","volume":"34","author":"Charbel Issa","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cytogfr.2025.06.005","article-title":"Neuroprotective properties of ciliary neurotrophic factor in the retina for the treatment of macular telangiectasia type 2","volume":"84","author":"Nystuen","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archopht.1982.01030030773010","article-title":"Idiopathic juxtafoveolar retinal telangiectasis","volume":"100","author":"Gass","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2010.02.013","article-title":"The prevalence of macular telangiectasia type 2 (MT2) in the beaver Dam Eye Study","volume":"150","author":"Klein","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.2147\/OPTH.S373538","article-title":"Macular telangiectasia type 2: a comprehensive review","volume":"16","author":"Kedarisetti","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R6-20261120","first-page":"123","article-title":"Anti-vascular endothelial growth factor treatment outcomes in macular telangiectasia: a systematic review","volume":"248","author":"Sriranganathan","year":"2025","journal-title":"Ophthalmologica"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1073\/pnas.89.23.11249","article-title":"Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light","volume":"89","author":"LaVail","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1038\/s41467-022-34443-x","article-title":"Ciliary neurotrophic factor-mediated neuroprotection involves enhanced glycolysis and anabolism in degenerating mouse retinas","volume":"13","author":"Do Rhee","year":"2022","journal-title":"Nat Commun"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1167\/iovs.10-6479","article-title":"Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment","volume":"52","author":"Talcott","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","article-title":"Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial","volume":"126","author":"Chew","year":"2019","journal-title":"Ophthalmology"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/XEB.0000000000000064","article-title":"Conducting systematic reviews of association (etiology): the Joanna Briggs Institute's approach","volume":"13","author":"Moola","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ajo.2014.12.013","article-title":"Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial","volume":"159","author":"Chew","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ophtha.2019.12.015","article-title":"Beyond performance metrics: automatic deep learning retinal OCT analysis reproduces clinical trial outcome","volume":"127","author":"Loo","year":"2020","journal-title":"Ophthalmology"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/IAE.0000000000001706","article-title":"Correlation of structural and functional outcome measures in a phase one trial of CNTF in type 2 idiopathic macular telangiectasia","volume":"38","author":"Sallo","year":"2018","journal-title":"Retina"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"EVIDoa2400481","DOI":"10.1056\/EVIDoa2400481","article-title":"Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2","volume":"4","author":"Chew","year":"2025","journal-title":"NEJM Evid"},{"key":"R22-20261120","doi-asserted-by":"crossref","first-page":"EVIDe2500127","DOI":"10.1056\/EVIDe2500127","article-title":"Ciliary neurotrophic factor\u2014a promising new therapy for macular telangiectasia type 2","volume":"4","author":"Duncan","year":"2025","journal-title":"NEJM Evid"},{"key":"R23-20261120","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1167\/iovs.16-20037","article-title":"Feasibility of macular integrity assessment (MAIA) microperimetry in children: sensitivity, reliability, and fixation stability in healthy observers","volume":"57","author":"Jones","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-20261120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.9.13.43","article-title":"Structure\u2013function analysis in macular drusen with mesopic and scotopic microperimetry","volume":"9","author":"Montesano","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"R25-20261120","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/IAE.0000000000001344","article-title":"Volume-rendered angiographic and structural optical coherence tomography angiography of macular telangiectasia type 2","volume":"37","author":"Spaide","year":"2017","journal-title":"Retina"},{"key":"R26-20261120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/bjophthalmol-2020-317131","article-title":"Deep learning-based classification and segmentation of retinal cavitations on optical coherence tomography images of macular telangiectasia type 2","volume":"106","author":"Loo","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R27-20261120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2016.07.013","article-title":"Long-term Follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants","volume":"170","author":"Birch","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R28-20261120","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/IAE.0000000000000064","article-title":"The dose-dependent macular thickness changes assessed by fd-oct in patients with retinitis pigmentosa treated with ciliary neurotrophic factor","volume":"34","author":"Pilli","year":"2014","journal-title":"Retina"},{"key":"R30-20261120","doi-asserted-by":"crossref","first-page":"155582","DOI":"10.1016\/j.cyto.2021.155582","article-title":"Role of IL-6 in the regulation of neuronal development, survival and function","volume":"144","author":"Kummer","year":"2021","journal-title":"Cytokine"},{"key":"R31-20261120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40291-025-00787-5","article-title":"Revakinagene taroretcel: first approval","volume":"29","author":"Hoy","year":"2025","journal-title":"Mol Diagn Ther"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:00:13Z","timestamp":1795140013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004852"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004852","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}